The role of interferon-α in the treatment of idiopathic myelofibrosis

Annals of Hematology

Volumn 78, Issue 12, 1999, Pages 533-538

  Bachleitner Hofmann, T ^a   Gisslinger, H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Idiopathic myelofibrosis; Interferon ; Pathogenesis; Prognosis; Treatment

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ALPHA2C INTERFERON; ANDROGEN; BASIC FIBROBLAST GROWTH FACTOR; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR; HEMOGLOBIN; MITOGENIC AGENT; OXYMETHOLONE; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT ERYTHROPOIETIN; TRANSFORMING GROWTH FACTOR BETA;

BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHROMOSOME ANALYSIS; DISEASE COURSE; HEMOGLOBIN DETERMINATION; HUMAN; LEUKOCYTE COUNT; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOCYTE;

EID: 0033408325     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050554     Document Type: Review

References (62)

1. Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R (1997) Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 98:1010-1016
2. Anger B, Janssen JWG, Schrezenmeier H, Hehlmann R, Heimpel H, Bartram CR (1990) Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms. Leukemia 4:258-261
3. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E (1988) A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 70:397-401
4. Barosi G, Liberato LN, Costa A, Buratti A, Di Dio F, Salvatore S, Ascari E (1990) Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia. Eur J Haematol 45 [Suppl 52]: 12-14
5. Barosi G, Ambrosetti A, Buratti A, Finelli C, Liberato NL, Quaglini S, Ricetti MM, Visani G, Tura S, Ascari E (1993) Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia 7:200-206
6. Barosi G, Liberato LN, Guarnone R (1993) Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 83:365-369
7. Barosi G, Ambrosetti A, Centra A, Falcone A, Finelli C, Foa P, Grossi A, Guarnone R, Rupoli S, Luciano L, Petti MC, Pogliani E, Russo D, Ruggeri M, Quaglini S (1998) Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood 91:3630-3636
8. Benbassat J, Penchas S, Ligumski M (1979) Splenectomy in patients with agnogenic myeloid metaplasia: an analysis of 321 published cases. Br J Haematol 42:207-214
9. Böhner H, Rötzscher VM, Tirier C, Heit W, Greiner J (1996) Splenektomie bei Osteomyelofibrose. Indikationen und Ergebnisse. Chirurg 67:1016-1019
10. Bourantas KL, Tsiara S, Christou L, Repousis P, Konstantinidou P, Bai M, Seferiadis K (1996) Combination therapy with recombinant human erythropoietin, interferon-α-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis. Acta Haematol 96:79-82
11. Brubaker LH, Briere J, Laszlo J, Kraut E, Landaw SA, Peterson P, Goldberg J, Donovan P (1982) Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone versus transfusions only. Arch Intern Med 142:1533-1537
12. Carlo-Stella C, Cazzola M, Ganser A, Barosi G, Dezza L, Meloni F, Pedrazzoli P, Hoelzer D, Ascari E (1987) Effects of recombinant α and γ interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 70:1014-1019
13. Cazzola M, Ponchio L, Beguin Y, Rosti V, Bergamaschi G, Liberato NL, Fregoni V, Nalli G, Barosi G, Ascari E (1992) Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 79:29-37
14. Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C, Montserrat E (1997) Identification of "short-lived" and "long-lived" patients at presentation of idiopathic myelofibrosis. Br J Haematol 97:635-640
15. Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, Pereira A, Montserrat E (1998) Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 102:684-690
16. Dalla KP, Zeigler ZR, Shadduck RK (1994) α-Interferon in myelofibrosis: a case report. Br J Haematol 86:654-656
17. Dalley A, Smith JM, Reilly JT, MacNeil S (1996) Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation. Br J Haematol 93:856-862
18. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88:1013-1018
19. Elliott MA, Chen MG, Silverstein MN, Tefferi A (1998) Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 103:505-511
20. Ganser A, Carlo-Stella C, Greher J, Völkers B, Hoelzer D (1987) Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 70:1173-1179
21. Gilbert HS (1998) Long-term treatment of myeloproliferative disease with interferon-α-2b. Feasibility and efficacy. Cancer 83:1205-1213
22. Gisslinger H, Linkesch W, Fritz E, Ludwig H, Chott A, Radaszkiewicz TH (1989) Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1:634-637
23. Gisslinger H, Forberg E, Eichinger S, Chott A, Geissler K, Lechner K (1996) Interferon alpha vs. interferon gamma in the treatment of idiopathic myelofibrosis. Ann Hematol 73 [Suppl 2]: A85 (abstract)
24. Groopman JE (1980) The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med 92:857-858
25. Guardiola P, Esperou H, Cazals-Hatem D, Ifrah N, Jouet JP, Buzyn A, Sutton L, Gratecos N, Tilly H, Lioure B, Gluckman E (1997) Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol 98:1004-1009
26. Hasselbalch H (1988) Hypothesis: a possible role for interferon in the treatment of idiopathic myelofibrosis. Med Hypotheses 27:345-348
27. Hasselbalch H (1988) Interferon in myelofibrosis. Lancet 1:355
28. Hasselbalch H (1990) Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol 34:291-300
29. Hasselbalch H, Jensen BA (1990) Prognostic factors in idiopathic myelofibrosis: a simple scoring system with prognostic significance. Eur J Haematol 44:172-178
30. Hasselbalch HC (1993) Idiopathic myelofibrosis - an update with particular reference to clinical aspects and prognosis. Int J Clin Lab Res 23:124-138
31. Hast R, Engstedt L, Jameson S, Killander A, Lundh B, Reizenstein P, Skarberg KO, Uden AM, Wadman B (1978) Oxymetholone treatment in myelofibrosis. Blut 37:19-26
32. Jack FR, Smith SR, Saunders PWG (1994) Idiopathic myelofibrosis: anaemia may respond to low-dose dexamethasone. Br J Haematol 87:877-878
33. Jacobson RJ, Salo A, Fialkow PJ (1978) Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51:189-194
34. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M, Leukemia Service (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response of interferon-α therapy. Ann Intern Med 122:254-261
35. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R (1997) Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 80:708-719
36. + hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 88:4534-4546
37. List AF, Doll DC (1992) Alpha-interferon in the treatment of idiopathic myelofibrosis. Br J Haematol 80:566-567
38. Löfvenberg E, Wahlin A (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41:375-381
39. Manoharan A (1988) Myelofibrosis: prognostic factors and treatment. Br J Haematol 69:295-298
40. Manoharan A (1991) Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol 77:252-254
41. Martyré MC, Magdelenat H, Bryckaert MC, Laine-Bidron C, Calvo F (1991) Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-β in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 77:80-86
42. Martyré MC, Magdelenat H, Calvo F (1991) Interferon-γ in vivo reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor-β in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 77:431-435
43. Martyré MC, Le Bousse-Kerdilès MC, Romquin N, Chevillard S, Praloran V, Demory JL, Dupriez B (1997) Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 97:441-448
44. McCarthy D, Clark J, Giles F (1991) The treatment of myelofibrosis with alfa-interferon. Br J Haematol 78:590-591
45. Njoku OS, Lewis SM, Catovsky D, Gordon-Smith EC (1983) Anaemia in myelofibrosis: its value in prognosis. Br J Haematol 54:79-89
46. Parmeggiani L, Ferrant A, Rodhain J, Michaux JL, Sokal G (1987) Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur J Haematol 39:228-232
47. Pietrasanta D, Clavio M, Vallebella E, Beltrami G, Cavaliere M, Gobbi M (1997) Long-lasting effect of cyclosporin-A on anemia associated with idiopathic myelofibrosis. Haematologica 82:458-459
48. Porcu P, Neiman RS, Orazi A (1999) Splenectomy in agnogenic myeloid metaplasia. Blood 93:2132-2134
49. Reilly JT (1994) Pathogenesis of idiopathic myelofibrosis: present status and future directions. Br J Haematol 88:1-8
50. Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, Potter A (1997) Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 98:96-102
51. Rodriguez JN, Martino ML, Muniz R, Prados D (1995) Recombinant human erythropoietin for the treatment of anemia in myelofibrosis with myeloid metaplasia. Am J Hematol 48:135-136
52. Rosenthal DS (1995) Myeloid metaplasia with myelofibrosis (agnogenic and postpolycythemia vera). In: Wasserman LR, Berk PD, Berlin NI (eds) Polycythemia vera and the myeloproliferative disorders. Saunders, Philadelphia, pp 259-291
53. Seewann HL, Gastl G, Lang A, Abbrederis K, Thaler J, Flener R, Huber C (1988) Interferon-alpha-2 in the treatment of idiopathic myelofibrosis. Blut 56:161-163
54. Silverstein MN, ReMine WH (1979) Splenectomy in myeloid metaplasia. Blood 53:515-518
55. Tefferi A, Silverstein MN (1994) Recombinant human erythropoietin therapy in patients with myelofibrosis and myeloid metaplasia. Br J Haematol 86:893
56. Tefferi A, Silverstein MN (1997) Agnogenic myeloid metaplasia. Cancer Invest 15:177-179
57. Thiele J, Kvasnicka HM, Werden C, Zankovich R, Diehl V, Fischer R (1996) Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma 22:303-317
58. Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, Gianni L, Zuffa E, Aloe-Spiriti MA, Latagliata R, Pileri S, Magrini U, Gugliotta L, Morra E, Bernasconi C, Mandelli F, Tura S (1990) Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75:4-9
59. Wang JC, Lang HD, Lichter S, Weinstein M, Benn P (1992) Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. Br J Haematol 80:184-188
60. Ward HP, Block MH (1971) The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine 50:357-420
61. Wickramasinghe SN, Peart S, Gill DS (1987) Alpha-interferon in primary idiopathic myelofibrosis. Lancet 2:1524-1525
62. Yataganas X, Meletis J, Plata E, Viniou N, Deligiannis F, Tsekoura C, Voscaridou E, Boussiotis V, Rombos J, Vayopoulos G, Kittas C, Fessas P (1991) Alpha interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis. Eur J Cancer 27 [Suppl 4]: S69-71